Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study

Digestive Diseases and Sciences

Volumn 61, Issue 9, 2016, Pages 2721-2731

  Pataky, Zoltan ^a   Genton, Laurence ^a   Spahr, Laurent ^a   Lazarevic, Vladimir ^a   Terraz, Sylvain ^a   Gaïa, Nadia ^a   Rubbia Brandt, Laura ^a   Golay, Alain ^a   Schrenzel, Jacques ^a   Pichard, Claude ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Fatty liver disease; Gut; Hypocaloric hyperproteic diet; Microbiota; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL DNA; GLUCOSE BLOOD LEVEL; PROTEIN INTAKE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEROIDALES; BACTEROIDES; BACTEROIDETES; BIFIDOBACTERIUM; BILIRUBIN BLOOD LEVEL; BLAUTIA; BODY COMPOSITION; BODY MASS; BODY WEIGHT; BUTYRICICOCCUS; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLOSTRIDIALES; FAECALIBACTERIUM; FAT MASS; FEMALE; FIRMICUTES; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEPATITIS; HUMAN; HYPOCALORIC HYPERPROTEIC DIET; INTESTINE FLORA; INTESTINE FUNCTION; INTRAABDOMINAL FAT; LACHNOSPIRACEAE; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; LOW CALORY DIET; MALE; METAGENOMICS; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN RESTRICTION; RUMINOCOCCACEAE; TAXONOMY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOSE TISSUE; CALORIC RESTRICTION; CLASSIFICATION; COHORT ANALYSIS; DIAGNOSTIC IMAGING; DIET THERAPY; DNA SEQUENCE; GENETICS; IMPEDANCE; LIVER; METABOLISM; MICROBIOLOGY; PROTEIN INTAKE; THERAPEUTIC USE;

ADIPOSE TISSUE; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BACTEROIDES; BLOOD GLUCOSE; BODY COMPOSITION; C-REACTIVE PROTEIN; CALORIC RESTRICTION; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLASSIFICATION; CLOSTRIDIALES; COHORT STUDIES; DIETARY PROTEINS; DNA, BACTERIAL; ELECTRIC IMPEDANCE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GASTROINTESTINAL MICROBIOME; HUMANS; INTRA-ABDOMINAL FAT; LIVER; MAGNETIC RESONANCE IMAGING; MALE; METAGENOMICS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OVERWEIGHT; PILOT PROJECTS; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TRIGLYCERIDES;

EID: 84965031173     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4179-1     Document Type: Article

References (48)

1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923.
2. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–384.
3. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609.
5. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79–104.
6. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–484.
7. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022–1023.
8. Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585–588.
9. Xiao S, Fei N, Pang X, et al. A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol. 2014;87:357–367.
10. Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120–127.
11. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601–609.
12. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374–1380.
13. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474.
14. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol (WJG). 2010;16:5286–5296.
15. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091–1103.
16. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12:224–229.
17. Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis—part I: review of principles and methods. Clin Nutr. 2004;23:1226–1243.
18. Kyle UG, Genton L, Karsegard L, Slosman DO, Pichard C. Single prediction equation for bioelectrical impedance analysis in adults aged 20–94 years. Nutrition. 2001;17:248–253.
19. Yu H, Shimakawa A, McKenzie CA, Brodsky E, Brittain JH, Reeder SB. Multiecho water-fat separation and simultaneous R2* estimation with multifrequency fat spectrum modeling. Magn Reson Med. 2008;60:1122–1134.
20. Deng J, Fishbein MH, Rigsby CK, Zhang G, Schoeneman SE, Donaldson JS. Quantitative MRI for hepatic fat fraction and T2* measurement in pediatric patients with non-alcoholic fatty liver disease. Pediatr Radiol. 2014;44:1379–1387.
21. Brennan DD, Whelan PF, Robinson K, et al. Rapid automated measurement of body fat distribution from whole-body MRI. AJR Am J Roentgenol. 2005;185:418–423.
22. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 1985;2004:2333–2338.
23. http://code.google.com/p/ea-utils. ea-utils: command-line tools for processing biological sequencing data. City.
24. Meyer F, Paarmann D, D’Souza M, et al. The metagenomics RAST server—a public resource for the automatic phylogenetic and functional analysis of metagenomes. BMC Bioinform. 2008;9:386.
25. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75:7537–7541.
26. Schmieder R, Edwards R. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS ONE. 2011;6:e17288.
27. Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26:2460–2461.
28. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J. 2012;6:610–618.
29. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73:5261–5267.
30. Overbeek R, Olson R, Pusch GD, et al. The SEED and the Rapid Annotation of microbial genomes using Subsystems Technology (RAST). Nucleic Acids Res. 2014;42:D206–D214.
31. Rho M, Tang H, Ye Y. FragGeneScan: predicting genes in short and error-prone reads. Nucleic Acids Res. 2010;38:e191.
32. Kent WJ. BLAT—the BLAST-like alignment tool. Genome Res. 2002;12:656–664.
33. Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol. 2013;59:138–143.
34. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995;57:289–300.
35. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes. 2005;54:603–608.
36. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49:80–86.
37. Larson-Meyer DE, Newcomer BR, Heilbronn LK, et al. Effect of 6-month calorie restriction and exercise on serum and liver lipids and markers of liver function. Obesity. 2008;16:1355–1362.
38. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–180.
39. Kakiyama G, Pandak WM, Gillevet PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58:949–955.
40. Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303:G675–685.
41. Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin gastroenterol Hepatol. 2013;11:e861–e863.
42. Louis P, Scott KP, Duncan SH, Flint HJ. Understanding the effects of diet on bacterial metabolism in the large intestine. J Appl Microbiol. 2007;102:1197–1208.
43. Eeckhaut V, Ducatelle R, Sas B, Vermeire S, Van Immerseel F. Progress towards butyrate-producing pharmabiotics: Butyricicoccus pullicaecorum capsule and efficacy in TNBS models in comparison with therapeutics. Gut. 2014;63:367.
44. Brahe LK, Astrup A, Larsen LH. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes Rev. 2013;14:950–959.
45. Endo H, Niioka M, Kobayashi N, Tanaka M, Watanabe T. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS ONE. 2013;8:e63388.
46. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11:577–591.
47. Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010;18:190–195.
48. Metges CC, Eberhard M, Petzke KJ. Synthesis and absorption of intestinal microbial lysine in humans and non-ruminant animals and impact on human estimated average requirement of dietary lysine. Curr Opin Clin Nutr Metab Care. 2006;9:37–41.